Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:MRUSNASDAQ:ZLABNYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$41.00+0.0%$42.41$17.86▼$58.40$3.26B-0.18865,499 shs959,240 shsMRUSMerus$43.57-1.8%$44.05$33.19▼$61.61$3.01B1.02720,781 shs479,065 shsZLABZai Lab$32.00-5.3%$33.27$15.05▼$39.77$3.51B1.09850,861 shs1.67 million shsZYMEZymeworks$12.57+0.4%$12.17$7.97▼$17.70$874.58M1.18618,050 shs370,378 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+3.39%+8.93%-9.39%+56.57%+102.32%MRUSMerus+6.05%+3.02%-5.58%+7.41%+5.69%ZLABZai Lab+0.54%+17.20%-4.52%+28.66%+115.84%ZYMEZymeworks+0.56%+8.59%-2.19%-14.19%+46.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics4.1553 of 5 stars4.52.00.04.72.21.70.0MRUSMerus3.1505 of 5 stars4.62.00.00.04.11.70.0ZLABZai Lab2.8596 of 5 stars3.43.00.00.03.42.50.6ZYMEZymeworks2.7233 of 5 stars3.40.00.00.04.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$76.2986.06% UpsideMRUSMerus 3.13Buy$85.3195.79% UpsideZLABZai Lab 2.75Moderate Buy$47.3748.02% UpsideZYMEZymeworks 2.88Moderate Buy$21.0067.06% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, ZLAB, AKRO, and MRUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/27/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/18/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/13/2025ZLABZai LabJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $51.003/11/2025ZYMEZymeworksLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.003/10/2025MRUSMerusBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$73.00 ➝ $70.003/10/2025ZYMEZymeworksHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$12.00 ➝ $13.003/7/2025ZLABZai LabScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/7/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $19.003/4/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$9.61 per shareN/AMRUSMerus$36.13M83.31N/AN/A$6.17 per share7.06ZLABZai Lab$398.99M8.79N/AN/A$8.05 per share3.98ZYMEZymeworks$76.30M11.46N/AN/A$6.63 per share1.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$151.76M-$3.75N/AN/AN/AN/A-32.46%-29.83%5/9/2025 (Estimated)MRUSMerus-$154.94M-$3.27N/AN/AN/A-680.61%-38.89%-31.16%5/6/2025 (Estimated)ZLABZai Lab-$334.62M-$2.59N/AN/AN/A-76.14%-36.97%-27.10%5/8/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.61N/AN/AN/A-182.75%-23.00%-18.04%5/8/2025 (Estimated)Latest ZYME, ZLAB, AKRO, and MRUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17N/AN/AN/AN/AN/A5/9/2025Q1 2025AKROAkero Therapeutics-$1.00N/AN/AN/AN/AN/A5/8/2025Q1 2025ZLABZai Lab-$0.33N/AN/AN/A$118.40 millionN/A5/8/2025N/AZYMEZymeworks-$0.45N/AN/AN/A$20.65 millionN/A2/28/2025Q4 2024AKROAkero Therapeutics-$0.98-$0.99-$0.01-$0.99N/AN/A2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 million2/27/2025Q4 2024ZLABZai Lab-$0.61-$0.80-$0.19-$0.80$110.15 million$109.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0517.2517.25MRUSMerusN/A8.328.32ZLABZai LabN/A3.012.87ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AMRUSMerus96.14%ZLABZai Lab41.65%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.94%MRUSMerus4.57%ZLABZai Lab13.88%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.62 million64.26 millionOptionableMRUSMerus3769.09 million65.34 millionOptionableZLABZai Lab1,950109.63 million94.24 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableZYME, ZLAB, AKRO, and MRUS HeadlinesRecent News About These CompaniesZymeworks Inc. Presents Promising Preclinical Data on Antibody-Drug Conjugates and T Cell Engagers at AACR Annual Meeting 2025April 25 at 1:44 PM | quiverquant.comZymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual MeetingApril 25 at 1:00 PM | globenewswire.comJump Financial LLC Makes New Investment in Zymeworks Inc. (NYSE:ZYME)April 25 at 4:13 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Geode Capital Management LLCApril 25 at 3:16 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Bought by Renaissance Technologies LLCApril 23 at 3:49 AM | marketbeat.com33,702 Shares in Zymeworks Inc. (NYSE:ZYME) Acquired by XTX Topco LtdApril 22 at 4:06 AM | marketbeat.comZymeworks Strengthens Clinical Leadership with New Senior VP AppointmentApril 21, 2025 | tipranks.comZymeworks Inc. Appoints Dr. Sabeen Mekan as Senior Vice President of Clinical DevelopmentApril 21, 2025 | quiverquant.comZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentApril 21, 2025 | financialpost.comZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentApril 21, 2025 | financialpost.comZymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical DevelopmentApril 21, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Director Acquires $825,315.48 in StockApril 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 73,953 SharesApril 19, 2025 | insidertrades.comWalleye Capital LLC Invests $6.63 Million in Zymeworks Inc. (NYSE:ZYME)April 18, 2025 | marketbeat.comZymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 17, 2025 | financialpost.comZymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025April 17, 2025 | globenewswire.comVanguard Group Inc. Lowers Stock Holdings in Zymeworks Inc. (NYSE:ZYME)April 15, 2025 | marketbeat.comWellington Management Group LLP Has $3.21 Million Stake in Zymeworks Inc. (NYSE:ZYME)April 14, 2025 | marketbeat.comAmerican Century Companies Inc. Takes Position in Zymeworks Inc. (NYSE:ZYME)April 14, 2025 | marketbeat.com201,700 Shares in Zymeworks Inc. (NYSE:ZYME) Bought by Norges BankApril 13, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Massachusetts Financial Services Co. MAApril 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME, ZLAB, AKRO, and MRUS Company DescriptionsAkero Therapeutics NASDAQ:AKRO$41.00 +0.01 (+0.02%) Closing price 04:00 PM EasternExtended Trading$40.99 -0.01 (-0.02%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Merus NASDAQ:MRUS$43.57 -0.79 (-1.78%) Closing price 04:00 PM EasternExtended Trading$43.56 -0.01 (-0.02%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Zai Lab NASDAQ:ZLAB$32.00 -1.80 (-5.33%) Closing price 04:00 PM EasternExtended Trading$32.00 0.00 (0.00%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Zymeworks NYSE:ZYME$12.57 +0.05 (+0.40%) Closing price 04:00 PM EasternExtended Trading$12.18 -0.40 (-3.14%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
